In an in vitro study, non-small-cell lung cancer (NSCLC) cells with PIK3CA mutations induced more effect responses of anti-proliferation and pro-apoptosis through the combined treatment of a dual PI3K/mTOR inhibitor and MEK inhibitor, compared to exclusive use [60]. This evidence concerns the gene MTOR and non-small cell lung carcinoma.